{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:27:39Z","timestamp":1786523259533,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:37:03Z","timestamp":1773909423000},"page":"182-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study"],"prefix":"10.1016","volume":"126","author":[{"given":"Ewen","family":"Anger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Josset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efg","family":"Vaugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Georges","family":"Riet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Ruffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Guerni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Barateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"De Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4873","authenticated-orcid":false,"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.03.020_bib0001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0002","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13938","article-title":"Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy","volume":"120","author":"De Bruycker","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0005","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ejso.2015.06.011","article-title":"Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged \u226566 years","volume":"41","author":"Abdollah","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0006","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: Meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/JU.0000000000001369","article-title":"Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: A systematic review and network meta-analysis","volume":"205","author":"Crocerossa","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0011","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0012","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","article-title":"Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: The OLI-P phase 2 clinical trial","volume":"5","author":"H\u00f6lscher","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0014","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: A prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0015","article-title":"Outcomes after a first and\/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT","volume":"28","author":"Gomez-Iturriaga","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ijc.32509","article-title":"Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial","volume":"146","author":"Bowden","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/1471-2407-14-671","article-title":"Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial","volume":"14","author":"Decaestecker","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: A multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0019","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0020","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/medicina59081442","article-title":"Stereotactic body radiotherapy for lymph-nodal oligometastatic prostate cancer: A multicenter retrospective experience","volume":"59","author":"Cuccia","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0021","doi-asserted-by":"crossref","first-page":"S2485","DOI":"10.1016\/S0167-8140(24)02299-0","article-title":"Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)","volume":"194","author":"Ost","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0022","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2024.03.039","article-title":"OLIGOPELVIS and the \u201call you can eat\u201d strategy for oligorecurrent nodal prostate cancer: Are we already full?","volume":"87","author":"Ost","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0023","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","article-title":"Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences","volume":"28","author":"Ost","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clon.2021.09.014","article-title":"Pattern of recurrence after stereotactic radiotherapy in prostate cancer patients with nodal pelvic relapse. A multi-institutional retrospective analysis","volume":"34","author":"Francolini","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0025","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: Definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0026","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2021.09.010","article-title":"An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation","volume":"164","author":"Slevin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2017.09.030","article-title":"Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review","volume":"125","author":"Murray","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0028","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year outcomes from PACE B: An international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0029","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0031","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.euo.2023.09.007","article-title":"PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute toxicity of a randomized phase 2 trial","volume":"7","author":"Ost","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110466","article-title":"Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort","volume":"199","author":"Alongi","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102176","article-title":"Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"95","author":"Munoz","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0034","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: A retrospective multicenter study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.euo.2023.03.005","article-title":"Salvage stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: A retrospective multicenter study","volume":"6","author":"Archer","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0037","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.prro.2024.05.009","article-title":"Urinary organs at risk for prostate cancer external beam radiation therapy: Contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy","volume":"14","author":"Le Gu\u00e9velou","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0038","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): A randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0040","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0041","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109527","article-title":"Applicability and usage of dose mapping\/accumulation in radiotherapy","volume":"182","author":"Murr","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.020_bib0043","doi-asserted-by":"crossref","first-page":"24TR01","DOI":"10.1088\/1361-6560\/ad0d8a","article-title":"Review and recommendations on deformable image registration uncertainties for radiotherapy applications","volume":"68","author":"Nenoff","year":"2023","journal-title":"Phys Med Biol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:34:12Z","timestamp":1786520052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162600502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S036030162600502X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.020","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}